CN119730868A - 用于治疗疼痛的肽和方法 - Google Patents
用于治疗疼痛的肽和方法 Download PDFInfo
- Publication number
- CN119730868A CN119730868A CN202380053577.6A CN202380053577A CN119730868A CN 119730868 A CN119730868 A CN 119730868A CN 202380053577 A CN202380053577 A CN 202380053577A CN 119730868 A CN119730868 A CN 119730868A
- Authority
- CN
- China
- Prior art keywords
- peptide
- seq
- pain
- peptides
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305773.8 | 2022-05-25 | ||
| EP22305773 | 2022-05-25 | ||
| PCT/EP2023/064091 WO2023227731A1 (en) | 2022-05-25 | 2023-05-25 | Peptides and methods for use in treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119730868A true CN119730868A (zh) | 2025-03-28 |
Family
ID=81975215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380053577.6A Pending CN119730868A (zh) | 2022-05-25 | 2023-05-25 | 用于治疗疼痛的肽和方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250213654A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4531886A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025519127A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250017221A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119730868A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129441A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023275937A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253053A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL317048A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014419A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202409064A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023227731A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026119985A1 (en) * | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating wounds and inflammatory diseases |
| WO2026119983A1 (en) | 2024-12-03 | 2026-06-11 | Tafalgie Therapeutics | Peptides for use in treating pain, wounds and inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| WO2006013462A2 (en) * | 2004-07-30 | 2006-02-09 | Nsgene A/S | Growth factors nsg28, nsg30, and nsg32 |
| CN103382220A (zh) * | 2012-05-03 | 2013-11-06 | 北京大学 | 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用 |
| EP2801369A1 (en) | 2013-05-06 | 2014-11-12 | Centre National De La Recherche Scientifique | TAFA4 compounds and uses thereof for treating pain |
| CN108699604A (zh) | 2016-03-08 | 2018-10-23 | 艾克斯-马赛大学 | 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途 |
-
2023
- 2023-05-24 AR ARP230101325A patent/AR129441A1/es unknown
- 2023-05-25 US US18/868,199 patent/US20250213654A1/en active Pending
- 2023-05-25 KR KR1020247041847A patent/KR20250017221A/ko active Pending
- 2023-05-25 IL IL317048A patent/IL317048A/en unknown
- 2023-05-25 AU AU2023275937A patent/AU2023275937A1/en active Pending
- 2023-05-25 CN CN202380053577.6A patent/CN119730868A/zh active Pending
- 2023-05-25 CA CA3253053A patent/CA3253053A1/en active Pending
- 2023-05-25 JP JP2024569387A patent/JP2025519127A/ja active Pending
- 2023-05-25 EP EP23728752.9A patent/EP4531886A1/en active Pending
- 2023-05-25 WO PCT/EP2023/064091 patent/WO2023227731A1/en not_active Ceased
- 2023-05-25 TW TW112119546A patent/TW202409064A/zh unknown
-
2024
- 2024-11-21 MX MX2024014419A patent/MX2024014419A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129441A1 (es) | 2024-08-28 |
| MX2024014419A (es) | 2024-12-06 |
| IL317048A (en) | 2025-01-01 |
| AU2023275937A1 (en) | 2024-12-12 |
| KR20250017221A (ko) | 2025-02-04 |
| CA3253053A1 (en) | 2023-11-30 |
| TW202409064A (zh) | 2024-03-01 |
| WO2023227731A1 (en) | 2023-11-30 |
| EP4531886A1 (en) | 2025-04-09 |
| JP2025519127A (ja) | 2025-06-24 |
| US20250213654A1 (en) | 2025-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wemmie et al. | Acid-sensing ion channels in pain and disease | |
| Freret et al. | Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat | |
| US20250221936A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| JP6625071B2 (ja) | 慢性疼痛用のナトリウムチャネルを標的とする非麻薬性crmp2ペプチド | |
| AU2017373651B2 (en) | Compositions comprising peptide wkdeagkplvk | |
| JP7097070B2 (ja) | クロライドチャネルの標的発現及びその使用方法 | |
| Del Bufalo et al. | Alpha9Alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain | |
| US20250213654A1 (en) | Peptides and methods for use in treating pain | |
| CN105377286B (zh) | 芋螺毒素(conotoxin)肽,其医药组合物和用途 | |
| WO2021008100A1 (zh) | 眼镜蛇神经毒素多肽对鸦片类药品痛觉过敏和耐受的抑制及对其镇痛的协同增效作用 | |
| CN118401249A (zh) | 用于治疗疼痛的肽和方法 | |
| CN114269384A (zh) | 调节肉毒杆菌神经毒素作用的组合物 | |
| JP2018529626A (ja) | サソリ毒耐熱合成ペプチド | |
| Tu et al. | Dexamethasone ameliorates recovery process of neuromuscular junctions after tourniquet-induced ischemia-reperfusion injuries in mouse hindlimb | |
| JP5746616B2 (ja) | ペプチドトキシンAPETx2の鎮痛作用 | |
| JP4581115B2 (ja) | そう痒性皮膚疾患の治療又は予防剤 | |
| EP1080111B1 (en) | The induction of antiobiotic peptides by lait (scd14) protein | |
| OA22072A (en) | Peptides and methods for use in treating pain. | |
| US20180030105A1 (en) | Therapeutic Compositions and Methods for Disorders Associated with Neuronal Degeneration | |
| KR20130122927A (ko) | Dkk2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도 | |
| OA22140A (en) | Peptides and methods for use in treating pain. | |
| Johnson et al. | AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease | |
| WO2026056985A1 (zh) | 抑郁症的治疗方法和药物组合物 | |
| KR20230097330A (ko) | Mls-stat3를 포함하는 루푸스 질환의 예방 또는 치료용 조성물 | |
| WO2020022518A1 (ja) | 筋萎縮性側索硬化症を含む神経疾患の予防剤及び/又は治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |